| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1784* | 2013 |
| Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ... Leukemia 22 (2), 414-423, 2008 | 1050 | 2008 |
| High-dose daunorubicin in older patients with acute myeloid leukemia B Löwenberg, GJ Ossenkoppele, W van Putten, HC Schouten, C Graux, ... New England Journal of Medicine 361 (13), 1235-1248, 2009 | 997 | 2009 |
| TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ... Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012 | 744 | 2012 |
| The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML S Kayser, K Doehner, J Krauter, CH Koehne, HA Horst, G Held, ... Blood, The Journal of the American Society of Hematology 117 (7), 2137-2145, 2011 | 540 | 2011 |
| Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group J Krönke, RF Schlenk, KO Jensen, F Tschürtz, A Corbacioglu, VI Gaidzik, ... Journal of Clinical Oncology 29 (19), 2709-2716, 2011 | 502 | 2011 |
| A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma A Glasmacher, C Hahn, F Hoffmann, R Naumann, H Goldschmidt, ... British journal of haematology 132 (5), 584-593, 2006 | 353 | 2006 |
| TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group VI Gaidzik, P Paschka, D Späth, M Habdank, CH Köhne, U Germing, ... Journal of clinical oncology 30 (12), 1350-1357, 2012 | 316 | 2012 |
| Clinical, molecular, and prognostic significance of WHO type inv (3)(q21q26. 2)/t (3; 3)(q21; q26. 2) and various other 3q abnormalities in acute myeloid leukemia S Lugthart, S Gröschel, HB Beverloo, S Kayser, PJM Valk, ... Journal of clinical oncology 28 (24), 3890-3898, 2010 | 295 | 2010 |
| Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG) VI Gaidzik, RF Schlenk, P Paschka, A Stoelzle, D Spaeth, A Kuendgen, ... Blood, The Journal of the American Society of Hematology 121 (23), 4769-4777, 2013 | 237 | 2013 |
| Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein M von Lilienfeld-Toal, MP Dietrich, A Glasmacher, L Lehmann, P Breig, ... European Journal of Clinical Microbiology and Infectious Diseases 23, 539-544, 2004 | 233 | 2004 |
| Secondary genetic lesions in acute myeloid leukemia with inv (16) or t (16; 16): a study of the German-Austrian AML Study Group (AMLSG) P Paschka, J Du, RF Schlenk, VI Gaidzik, L Bullinger, A Corbacioglu, ... Blood, The Journal of the American Society of Hematology 121 (1), 170-177, 2013 | 230 | 2013 |
| Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party … SC Mellinghoff, J Panse, N Alakel, G Behre, D Buchheidt, M Christopeit, ... Annals of hematology 97, 197-207, 2018 | 219 | 2018 |
| Invasive fungal infection: new treatments to meet new challenges M von Lilienfeld-Toal, J Wagener, H Einsele, OA Cornely, O Kurzai Deutsches Ärzteblatt International 116 (16), 271, 2019 | 211 | 2019 |
| Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German … WJ Heinz, D Buchheidt, M Christopeit, M von Lilienfeld-Toal, OA Cornely, ... Annals of hematology 96, 1775-1792, 2017 | 202 | 2017 |
| Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies S Kayser, M Zucknick, K Doehner, J Krauter, CH Koehne, HA Horst, ... Blood, The Journal of the American Society of Hematology 119 (2), 551-558, 2012 | 201 | 2012 |
| COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety A Fendler, EGE de Vries, CH GeurtsvanKessel, JB Haanen, B Wörmann, ... Nature Reviews Clinical Oncology 19 (6), 385-401, 2022 | 197 | 2022 |
| CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are decreased in the peripheral blood of … S Feyler, M Von Lilienfeld‐Toal, S Jarmin, L Marles, A Rawstron, ... British journal of haematology 144 (5), 686-695, 2009 | 196 | 2009 |
| COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry MM Rüthrich, C Giessen-Jung, S Borgmann, AY Classen, S Dolff, ... Annals of hematology 100, 383-393, 2021 | 184 | 2021 |
| Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German … M Kochanek, E Schalk, M von Bergwelt-Baildon, G Beutel, D Buchheidt, ... Annals of hematology 98, 1051-1069, 2019 | 183 | 2019 |
Axel GlasmacherUniversity of BonnVerificeret mail på uni-bonn.de
